# Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

> **NCT07482176** · PHASE3 · RECRUITING · sponsor: **Adverum Biotechnologies, Inc.** · enrollment: 284 (estimated)

## Conditions studied

- Neovascular Age-Related Macular Degeneration (nAMD)
- Wet AMD

## Interventions

- **GENETIC:** Ixo-vec
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT07482176
- **Lead sponsor:** Adverum Biotechnologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-16
- **Primary completion:** 2027-11-15
- **Final completion:** 2031-10-20
- **Target enrollment:** 284 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07482176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07482176, "Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07482176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*